Usana Health Sciences IncUSNA
Price$14.47

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $913.4M+6.9% YoYTTM through 4 Jul 2026
Net Income -$22.2M-152.7% YoYTTM through 4 Jul 2026
Free Cash Flow $15.9MTTM through 4 Jul 2026

Margins

Current
Gross Margin77.4%
EBITDA Margin3.4%
Operating Margin-0.1%
Net Margin-2.4%

Returns

-4.2%ROE
-3.2%ROA

Balance Sheet Health

Debt / Equity0.03x
Current Ratio2.66x
Net Debt-$149Mnet cash position
Cash & Equivalents$168.6M

Quality Metrics

Altman Z-Score3.73
Piotroski F-Score5 / 9
FCF Margin1.7%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'21'22'22'23'24'26
FY2026: $925.3M
Diluted EPS-$1.18TTM
'19'21'22'22'23'24'26
FY2026: $0.58

Dividend

No dividend

Capital Allocation

R&D Spend$10.7M
Capex Intensity1.3%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.